Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Monoclonal antibodies (Mabs) against the Urbani strain of the SARS-associated coronavirus (SARS-CoV) were developed and characterized for reactivity to SARS-CoV and SARS-CoV S, N, M, and E proteins using enzyme-linked immunoabsorbent (ELISA), radioimmunoprecipitation, immunofluorescence, Western Blot and microneutralization assays. Twenty-six mAbs were reactive to SARS-CoV by ELISA, and nine were chosen for detailed characterization. Five mAbs reacted against the S protein, two against the M protein, and one each against the N and E proteins. Two of five S protein mAbs neutralized SARS-CoV infection of Vero E6 cells and reacted to an epitope within amino acids 490-510 in the S protein. While two of the three non-neutralizing antibodies recognized at second epitope within amino acids 270-350. The mAbs characterized should prove useful for developing SARS-CoV diagnostic assays and for studying the biology of infection and pathogenesis of disease.
Tripp
Ralph A
RA
National Centers for Infectious Diseases, Division of Viral and Rickettsial Diseases, Respiratory and Enteric Virus Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Mailstop G-09, Atlanta, GA 30333, USA.
Haynes
Lia M
LM
Moore
Deborah
D
Anderson
Barbara
B
Tamin
Azaibi
A
Harcourt
Brian H
BH
Jones
Les P
LP
Yilla
Mamadi
M
Babcock
Gregory J
GJ
Greenough
Thomas
T
Ambrosino
Donna M
DM
Alvarez
Rene
R
Callaway
Justin
J
Cavitt
Sheana
S
Kamrud
Kurt
K
Alterson
Harold
H
Smith
Jonathan
J
Harcourt
Jennifer L
JL
Miao
Congrong
C
Razdan
Raj
R
Comer
James A
JA
Rollin
Pierre E
PE
Ksiazek
Thomas G
TG
Sanchez
Anthony
A
Rota
Paul A
PA
Bellini
William J
WJ
Anderson
Larry J
LJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology*; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology*; D000918:Antibody Specificity; D002460:Cell Line; D002522:Chlorocebus aethiops; D000086862:Coronavirus M Proteins; D000086462:Coronavirus Nucleocapsid Proteins; D018604:Epitope Mapping; D006801:Humans; D008562:Membrane Glycoproteins / Q000276:immunology; D009500:Neutralization Tests; D019590:Nucleocapsid Proteins / Q000276:immunology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000821:virology; D064370:Spike Glycoprotein, Coronavirus; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000276:immunology; D014763:Viral Matrix Proteins / Q000276:immunology; D015678:Viral Structural Proteins / Q000276:immunology*; D000086082:Viroporin Proteins
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000086862:Coronavirus M Proteins; D000086462:Coronavirus Nucleocapsid Proteins; C501689:E protein, SARS coronavirus; C000706237:M protein, SARS-CoV; D008562:Membrane Glycoproteins; D019590:Nucleocapsid Proteins; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins; D014763:Viral Matrix Proteins; D015678:Viral Structural Proteins; D000086082:Viroporin Proteins; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus